tbuckley/cabot-search huggingface dataset:
MRI findings in women with triple negative breast cancer.
Authors: SL Hines, SA McLaughlin, LA Vallow
Journal: Cancer Research (2009)

Abstract Abstract #4014 Background&amp;#x2028; Preoperative magnetic resonance imaging (MRI) of the breasts in women with breast cancer (BC) has improved the detection of occult ipsilateral (I/L) and contralateral (C/L) malignancies. Breast MRI findings in patients with estrogen receptor (ER), progesterone receptor (PR), and HER2 negative (triple negative (TN)) disease have not been previously reported. Women with TN BC are at increased risk of distant metastases and a reduced survival vs. BC patients as a whole. One potential explanation may be the presence of occult disease. The role of bilateral breast MRI in these patients remains to be determined.&amp;#x2028; Hypothesis&amp;#x2028; Patients with TN BC are more likely to have occult malignancy identified by preoperative MRI vs. those with non-TN BC.&amp;#x2028; Methods&amp;#x2028; All newly diagnosed BC patients from 2003-2007 were reviewed. Information on age, race, histology, ER, PR, HER2, staging, treatment, MRI findings, subsequent investigations, and additional cancer diagnoses was recorded. The incidence of additional I/L or C/L malignany was calculated. The percentage of total patients initially felt to be candidates for partial breast irradiation who required a change in their cancer management was calculated.&amp;#x2028; Results&amp;#x2028; 55 (11%) were diagnosed with TN BC, of whom 52 women completed preoperative MRI. 456 (89%) had non-TN BC; 421 completed preoperative MRI. The median age among TN and non-TN patients was 62 years (Table 1). A majority of women in both groups were Caucasian. African-American women were more likely to be diagnosed with TN vs. non-TN disease (11% vs. 6%).&amp;#x2028; &amp;#x2028; I/L BC was documented in 13/52 (25%) of TN patients vs. 25% of non-TN patients. No C/L cancers were detected in the TN group (6% in the non-TN group). Of the TN group, 15 patients required a change in their treatment (29%) based on findings from MRI vs. 32% of non-TN patients.&amp;#x2028; Conclusions&amp;#x2028; Patients with a new diagnosis of TN BC are not at increased risk of occult malignancy than those with non-TN BC. 25% of patients with TN BC had additional I/L disease not previously detected on clinical examination, mammogram, or ultrasound. Of those with non-TN BC, 25% were diagnosed with an additional I/L and 6% with C/L malignancy. The benefit of MRI was limited by false positives, with a number of patients in both groups undergoing a benign biopsy.&amp;#x2028; These results suggest that patients with TN BC are not more likely than those with non-TN disease to have additional occult I/L or C/L cancer. The incidence of additional disease remains high and preoperative MRI may be beneficial. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4014.
Redefining Blood-Pressure Targets — SPRINT Starts the Marathon
Authors: Vlado Perkovic, Anthony Rodgers
Journal: New England Journal of Medicine (2015)

Blood pressure is a potent determinant of cardiovascular risk, but the most appropriate targets for blood-pressure lowering have long been debated. Observational studies with a low risk of confounding have shown a linear relationship between blood pressure and cardiovascular risk down to 115/75 mm Hg,1 but some observational studies with a greater potential for confounding, involving persons at increased risk, have suggested a J-shaped curve — that is, below a given blood pressure, risk would increase. When trials of blood-pressure–lowering drugs have shown benefits in patients without hypertension, these effects have often been ascribed to alternative mechanisms. The widespread uncertainty . . .
Abstract 3674: Inhibition of noncanonical NF-kappa B activation by (−)-DHMEQ in vitro and in adult T-cell leukemia cells
Authors: Masatoshi TAKEIRI, Ryoichi HORIE, Kazuo UMEZAWA
Journal: Cancer Research (2010)

Abstract [Objective and Rationale]Noncanonical NF-kappa B consisting of RelB and p52 is especially important for the maturation of B-lymphocytes and autoimmune diseases. In one hand, we have designed and synthesized a novel NF-kappa B inhibitor (−)-DHMEQ. It showed potent anti-inflammatory and anti cancer effects in animal models without any toxicity. We have reported (−)-DHMEQ covalently binds to the specific Cys residue of each NF-kappa B component and that it inhibits the DNA binding of canonical NF-kappa B components. However, the effects on noncanonical NF-kappa B has not been studied at the molecular level. In the present research we have studied theinhibitory effect of (−)-DHMEQ on noncanonical NF-kappa B in vitro and in cultured lymphoma cells in which noncanonical NF-kappa B is constitutively activated. [Experimental Design and Results]We prepared recombinant noncanonical NF-kappa B proteins, RelB and p52. (−)-DHMEQ was shown to covalently bind to Cys144 of RelB but not to p52 in MLADI-TOF/MS and mutation analysis. Either RelB or p52 does not form homodimer. Then, we prepared HeLa cells over–expressing full length RelB and p52. (−)-DHMEQ inhibited the NF-kappa B activity in RelB(wild type)/p52 cells but not in RelB(C144S)/p52 expressing cells in EMSA. Thus (−)-DHMEQ was shown to target Cys 144 of RelB in cultured cells to inhibit noncanonical NF-kappa B-DNA binding. It also inhibited RelB/p52 binding to DNA in vitro. Then, we looked for the cell line in which noncanonical NF-kappa B is constitutively activated using anti-RelB in EMSA. MT-1 cells are HTLV-1 transformed T-cells and often used for the adult T-cell leukemia (ATL) model. We found that the highly activated NF-kappa B is mainly consisting with noncanonical one in MT-1 cells. (−)-DHMEQ effectively inhibited the noncanonical NF-kappa B activity in MT-1 cells. [Conclusion] (−)-DHMEQ binds to RelB and effectively inhibited RelB/p52-DNA binding. We have found noncanonical NF-kappa B is highly activated ATL-like MT-1 cells, which was inhibited by (−)-DHMEQ. (−)-DHMEQ may be useful for the treatment of ATL and other diseases induced by noncanonical NF-kappaB activation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3674.
A BASELINE PD/PA OF ≤ 0.86 OBVIATES THE NEED FOR FFR MEASUREMENT AND ADENOSINE INFUSION IN INTERMEDIATE CORONARY STENOSES: A LARGE TERTIARY CARE EXPERIENCE
Authors: Syed Shahab Kazmi, Arsalan Riaz, Mirza Nubair Ahmad, Fatima A Husain, Imran Husain, Haroon Yousaf, Saagar Shah, Khawaja Afzal Ammar, Anjan Gupta
Journal: Journal of the American College of Cardiology (2015)
TCT-152 ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six Month Phase I Safety Results
Authors: Raj Makkar, Richard Schatz, Jay H. Traverse, Andrew Hamer, Katherine Beattie, Rachel R. Smith, Frances Kivel, Linda Marban, Eduardo Marban, Timothy D. Henry
Journal: Journal of the American College of Cardiology (2014)
The Febrile Convulsion in Shigellosis
Authors: Muriel Kowlessar, Gilbert B. Forbes
Journal: New England Journal of Medicine (1958)

A NUMBER of clinical analyses of the febrile convulsion are available in the literature,1 but with few exceptions the analytical procedure has been approached from the standpoint of the convulsion as the symptom that brings the patient to the clinic, thus permitting him to be included in the study series. In an effort to bring the problem into sharper focus, we have approached the subject from a different point of view — namely, the study of a series of patients suffering from a disease that in our experience was associated with a high prevalence of Central-nervous-system symptoms. To this purpose, . . .
Patent Ductus Arteriosus Causing Infradiaphragmatic Activity on Perfusion Lung Scintigraphy
Authors: ROBERT D. A. JOHNSON, DANIEL F. WORSLEY
Journal: Clinical Nuclear Medicine (1996)

A 23-year-old woman presented with known pulmonary hypertension caused by a patent ductus arteriosus. As part of the pre-lung transplant assessment, the patient underwent quantitative ventilation/perfusion lung scintigraphy to determine regional lung function. Results of perfusion scintigraphy showed infradiaphragmatic activity within the spleen and kidneys that indicated a right-to-left shunt, which is secondary to a patent ductus arterios with Eisenmenger's physiology. An image of the brain did not show the expected cortical activity, which is normally seen in patients with intrapulmonary or intracardiac right-to-left shunts. This finding is anatomically understandable because right-to-left shunts, which are secondary to a patent ductus arteriosus with Eisenmenger's physiology, enter the proximal descending thoracic aorta distal to the origin of the great vessels of the head and neck.
Abstract 2653: Nelfinavir induces apoptosis in hormone-resistant prostate cancer cells through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6
Authors: Min Guan
Journal: Cancer Research (2011)

Abstract We previously reported that nelfinavir-induced apoptosis in liposarcoma is a direct result of regulated intramembrane proteolysis (RIP) inhibition mediated through inhibition of site-2 protease (S2P) activity. We now report similar effects in hormone-resistant prostate cancer (HR-PC) cells. Nelfinavir-mediated RIP inhibition leads to accumulation of unprocessed sterol regulatory element binding protein-1 (SREBP-1) and activating transcription factor 6 (ATF6). This results in endoplasmic reticulum (ER) stress and inhibition of the unfolded protein response (UPR), which leads to autophagy and caspase activation. Confocal microscopy and proliferation studies demonstrate that nelfinavir inhibits the nuclear translocation of SREBP-1-EGFP and ATF6-EGFP fusion proteins, and reduces PC proliferation, similar to the situation observed in site-1 protease (S1P) and S2P-siRNA knockdown cells. Western blotting in nelfinavir and S1P and/or S2P-siRNA knockdown cells confirms accumulation of precursor SREBP-1 and ATF6. Treatment of PC cells with DCI, an S1P inhibitor did not affect SREBP-1 processing. In contrast, 1,10-phenanthroline, an S2P inhibitor, reproduces the molecular and biological phenotype observed in nelfinavir-treated HR-PC cells. These results are consistent with the hypothesis that S2P is a target of nelfinavir. These findings, together with our previous report, provide new insight into the mechanism of nelfinavir-mediated induction of ER stress and cell death in cancer, and are the first to report targeting S2P therapeutically for cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2653. doi:10.1158/1538-7445.AM2011-2653
Abstract 2228: mTORC2 is a promising therapeutic target in epithelial ovarian cancer
Authors: Takeshi Hisamatsu, Seiji Mabuchi, Kae Hashimoto, Aki Isobe, Kenjiro Sawada, Tadashi Kimura
Journal: Cancer Research (2012)

Abstract Purpose: The mammalian target of rapamycin (mTOR) is frequently activated in epithelial ovarian cancer, and is regarded as an attractive therapeutic target for therapy. Preclinical investigations using rapamycin and its analogs have demonstrated significant growth-inhibitory effects on the growth of ovarian cancer, but those researches were focused only on mTOR Complex 1 (mTORC1), not on mTOR Complex 2 (mTORC2). We investigated the activity of mTORC2 and its role in epithelial ovarian cancer. Experimental design: Using human ovarian cancer samples and cell lines, (serous adenocarcinoma and clear cell carcinoma), we first examined the expression and activity of mTORC2. We next investigated the role of mTORC2 on the proliferation and invasiveness of overian cancer cells by knocking down the expression of rictor. Moreover, using 2 pairs of everolimus-sensitive parental and everolimus-resistant sublines, we examined whether mTORC2 is involved in the mechanism of acquired resistance to everolimus. Results: mTORC2 is frequently activated in human ovarian cancer, especially in clear cell carcinoma of the ovary. mTORC2 stimulated the proliferation and invasiveness of ovarian cancer cells in vitro. mTORC2 was hyperactivated in everolimus-resistant sublines compared to their parental cell lines. Inhibition of mTORC2 activity by siRNA sensitize the everolimus-resistant ovarian cancer cells to everolimus. Conclusion: mTORC2 is frequently activated in epithelial ovarian cancer, and is a promising therapeutic target. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2228. doi:1538-7445.AM2012-2228
Integrating Genotype in Risk Classification for Gist Recurrence. a Spanish Group for Sarcoma Research (Geis) Study
Authors: J. Martin Broto, S. Calabuig, J. Rubio, A. Gutierrez, J. Duran, F. Garcia, J. Martinez-Trufero, J. Maurel, X. García Del Muro, J. Cruz, R. Cubedo, A.M. Poveda, C. Valverde Morales, L.M. De Sande González, A. De Juan, J.A. Lopez-Guerrero
Journal: Annals of Oncology (2014)
Abstract 221: Cancer stem cell-selected patient-derived xenograft models with sensitivity to FAK and Pan-PI3K/mTOR inhibitors .
Authors: David T. Weaver, Daniel Paterson, Mahesh Padval, Jonathan Pachter, Michael Lewis
Journal: Cancer Research (2013)

Abstract In this study, Tumor-initiating (Creighton et al, 2009) and EMT gene expression signatures (Gupta et al., 2009, Taube et al, 2009) were used as classifiers. Tumors from 25 human triple negative breast cancer Patient-Derived Xenografts (PDX) were examined with Affymetrix U133Plus2 RNA arrays. Datasets were RMA normalized, and samples scored with the TI or EMT signature based on the Pearson Correlation Coefficient of a vector of mean-centered expression values of signature genes and a vector of indicators for signature genes such that 1 (up-regulated, correlated) genes and -1 (down-regulated, anti-correlated) genes formed a TI or EMT score. A high EMT score is also representative of mesenchymal tumors. Several of the triple negative breast cancer PDX models had both high TI and high EMT scores, indicated by p&amp;lt;0.05 of a one-sided Pearson Correlation Coefficient test. Two of the PDX models with high positive TI and EMT scores, 4664 and 3887, were evaluated for sensitivity to a FAK inhibitor (VS-4718), a pan-PI3K/mTOR inhibitor (VS-5584), and chemotherapy (docetaxel). FAK and PI3K/mTOR are implicated in tumorigenesis, including tumor initiation, growth, angiogenesis and metastasis. Both 4664 and 3887 tumors were N-cadherin-positive (mesenchymal), and strongly positive for CD44 (TI marker) by immunohistochemistry. These tumors were also weakly positive for E-cadherin and highly heterogeneous for pan-cytokeratin, two epithelial marker patterns suggesting a mesenchymal phenotype. Whereas 3887 was Notch3-positive, 4664 was Notch3-negative. VS-4718-treated 4664 and 3887 models showed diminished tumor growth over 21 days compared with vehicle-treated animals. VS-4718-treated animal tumors showed decreased FAK autophosphorylation (pY397) by immunohistochemistry. Likewise, the VS-5584-treated 4664 and 3887 animals blocked tumor growth over 21 days. In these models, the PI3K/mTOR pathways activate downstream signaling phosphorylation of pS6 pSer240/244, p4EBP1 pThr70, and pPRAS40 pThr246. In the VS-5584-treated 3887 tumors, pS6 pSer240/244 levels were significantly diminished relative to vehicle- and docetaxel-treated tumors. As predicted by TI and EMT gene expression indicators, both models were docetaxel-resistant. These findings and our previous work on these agents for the inhibition of CSCs support the clinical development of the FAK and the pan-PI3K/mTOR inhibitors to target CSCs for treatment of breast, mesothelioma, ovarian and other cancers. Citation Format: David T. Weaver, Daniel Paterson, Mahesh Padval, Jonathan Pachter, Michael Lewis. Cancer stem cell-selected patient-derived xenograft models with sensitivity to FAK and Pan-PI3K/mTOR inhibitors . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 221. doi:10.1158/1538-7445.AM2013-221
FRI0297 The burden of dryness. a comprehensive overview from the perspective of patients with sjögren’s syndrome
Authors: N. Van Leeuwen, M. Schipper, L. Schueler-de Kort, R. Geenen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The chronic autoimmune disease Sjögren's syndrome is characterized by infiltration of the exocrine glands. The resulting dryness of eyes, mouth, and other parts of the body may have serious consequences for daily life functioning and well-being. Although dryness is the key feature of Sjögren's syndrome, its consequences of dryness for daily life have not been systematically studied. <h3>Objectives</h3> Aim of this study was to identify a comprehensive overview of the consequences of dryness as perceived by patients with Sjögren's syndrome. <h3>Methods</h3> Interviews were held with ten patients to yield statements about the consequences of dryness of patients with Sjögren's syndrome. Thirty patients individually sorted the resulting 70 statements according to similarity. Hierarchical cluster analysis was used to structure the consequences of dryness. <h3>Results</h3> The hierarchical structure of dryness showed a higher-order distinction between statements reflecting 'Generic' and 'Disease specific' consequences (Figure). The lowest level consisted of 9 clusters. The "Quality of life" cluster included general consequences for quality of life that are also observed in other diseases. The cluster "Disease-specific" was subdivided into 1) consequences reflecting primary symptoms in the "Eyes" and "Mouth", 2) burden of the disease such as "Participation" in social activities, "Somatic" problems involving the whole body, and problems with "Intimacy", and 3) miscellaneous consequences such as "Sensitivity", "Dry hair", and use of "Aids" to deal with consequences of dryness. <h3>Image/graph</h3> <h3>Conclusions</h3> This study is the first to identify and structure consequences of dryness from the perspective of patients with Sjögren's syndrome. The overview can be used as an assessment instrument to get a quick impression of consequences of dryness that are important for an individual patient. Moreover, the overview can be applied in therapeutic goal setting, in the development of a questionnaire, in the construction of interventions aimed to relieve the burden of dryness, and in the evaluation of medical and non-medical interventions or education. <h3>Acknowledgements</h3> Funded by: National Association Sjögren Patients, Dutch Arthritis Association. <b>Disclosure of Interest</b>: None Declared
99mTc-MDP– and 18F-FDG–Avid Florid Reactive Periostitis Ossificans Mimicking Recurrent Osteosarcoma
Authors: Byung Hyun Byun, Jae-Soo Koh, Ji Young Yoo, Sang Moo Lim, Chang-Bae Kong
Journal: Clinical Nuclear Medicine (2013)

Florid reactive periostitis ossificans is a rare benign lesion usually affecting the tubular bones of the hands and feet, and its histological features may be confused with those of infection and osteosarcoma. We report a case with florid reactive periostitis ossificans of the femur showing increased tracer uptake on both 99mTc-MDP bone scan and 18F-FDG PET/CT mimicking a local recurrence in a 15-year-old patient with high-grade osteosarcoma.
P122 A Survey Of Pulmonary Rehabilitation (pr) Services In Kent, Surrey, Sussex (kss)
Authors: J.-P. Crofton-Biwer, E. Lazar, J. Bott
Journal: Thorax (2014)

<h3>Introduction and objectives</h3> There is no agreed model for Pulmonary Rehabilitation (PR) and wide variation in services exists. A regional PR network was established 4 years ago, with the aim to drive up standards and reduce variation. An audit was undertaken of all PR services in the region to determine costs of services and factors influencing variance. <h3>Method</h3> In June 2013 e-questionnaires were sent to all 16 known PR providers; fifty questions requested average annual/weekly data including: staff pay bands, time spent on exercise, education, administration, travel and other identifiable costs, numbers failing to complete (drop-out) and clinical outcomes. All costs were calculated in terms of cost-per-patient. Providers were assured actual costs and their identity would not be revealed. <h3>Results</h3> PR regionally serviced 3712 patients annually Many providers total per patient costs were above the national tariff Administration formed the highest share of providers total cost (24%), Administration time per patient per course varied widely (1 – 14 h) There was a wide range of drop-out, 10–42%, mean 23% The mean (£76) and range (£23-£255) of drop-out cost per patient was high, rising at an ever increasing rate for every dropout (Figure) Both larger patient numbers and rolling programmes were associated with higher per patient cost, the latter accountable to higher admin costs surpassing savings in exercise session costs. Inconsistent reporting of clinical outcome data by providers. <h3>Conclusion</h3> Our analysis demonstrates significant variation in the makeup of providers’ individual costs, with the majority of the variation between providers’ total cost per patient attributed to dropouts. Administration and drop-out were the greatest contributory factors to higher service costs. Higher cost was associated with larger patient numbers and rolling programmes. <h3>Discussion</h3> Insufficient clinical outcome data were received to make any meaningful comparison of cost with outcome. Further work in this area is therefore required. Providers expected that providing services for larger numbers of patients and using rolling programmes would have lower costs, but the reverse was true. Administration costs for PR are very significant and may frequently be the key driver behind cost differences.
A Case of Cap Polyposis Investigated by Scintigraphy With Human Serum Albumin Labeled With Tc-99m DTPA
Authors: SUSUMU SHIOMI, YOSHINORI MORIYAMA, NOBUHIDE OSHITANI, TAKAYUKI MATSUMOTO, TETSUO KUROKI, JOJI KAWABE, HIRONOBU OCHI, CHIO OKUYAMA
Journal: Clinical Nuclear Medicine (1998)

Cap polyposis is a rare intestinal disease that can be difficult to differentiate from inflammatory bowel disease. When cap polyposis is suspected, it is important to confirm protein loss. A 54-year-old woman who had been treated for ulcerative colitis for 7 years had severe hypoproteinemia. Scintigraphy with Tc-99m-labeled DTPA complexed with human serum albumin showed protein loss from the descending colon. Left hemicolectomy and sigmoid colectomy were performed. Cap polyposis was diagnosed on the basis of histologic findings from an operative specimen. The patient's diarrhea resolved after surgery and her hypoproteinemia improved. Scintigraphy with this label gave information helpful in the diagnosis of cap polyposis.
P946 COMPARISON OF THE EFFICACY OF RIFAXIMIN VS NORFLOXACIN IN THE PREVENTION OF NOSOCOMIAL MULTIRESISTANT BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS
Authors: J.M. Ramos, I. Vidal, P. Bellot, R. Francés, J. González-Navajas, P. Zapater, J. Such
Journal: Journal of Hepatology (2014)